⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

July 1, 2026The Lancet

Pregnancy as exclusion criterion in Ebola research: not again

Lisa Schwartz Eman Ahmed Ana Palmero Calvin Wai-Loon Ho Raffaella Ravinetto

View at Publisher

Ask AI

Bookmark

Share

Key Points

This paper examines the implications of excluding pregnant individuals from Ebola research.
Literature review of current Ebola research practices
Analysis of ethical frameworks regarding pregnancy in clinical trials
Discussion of public health impacts affecting pregnant individuals
Exclusion harms the understanding of Ebola's effects on pregnancy and fetuses.
It perpetuates health disparities for pregnant individuals during outbreaks.
Recommendations include reevaluation of ethical guidelines to include pregnant individuals in research.

No abstract yet

We only have this paper's title and publication details.

Read it at the source→

Implication

The paper critiques exclusion of pregnant individuals in Ebola trials, highlighting ethical and public health implications.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Schwartz et al. (2026) studied this question.

synapsesocial.com/papers/6a62d9b0d8aa0f02ee9ceee6 https://doi.org/10.1016/s0140-6736(26)01367-x

View at Publisher

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 related papers. Consider them for comparative context:

1Advancing maternal and perinatal health through clinical trials: key insights from a WHO global consultationClinical Trial · 2025 · 31 citations
2A Randomized, Controlled Trial of Ebola Virus Disease TherapeuticsClinical Trial · 2019 · 1,611 citations
3The Exclusion of Pregnant, Pregnable, and Once-Pregnable People (a.k.a. Women) from Biomedical ResearchOriginal Research · 1993 · 66 citations
4Patiromer versus placebo to enable spironolactone use in patients with resistant hypertension and chronic kidney disease (AMBER): a phase 2, randomised, double-blind, placebo-controlled trialThe Lancet · 2019
5Efficacy of catheter-based renal denervation in the absence of antihypertensive medications (SPYRAL HTN-OFF MED Pivotal): a multicentre, randomised, sham-controlled trialThe Lancet · 2020

Catheter-based renal denervation in patients with uncontrolled hypertension in the absence of antihypertensive medications (SPYRAL HTN-OFF MED): a randomised, sham-controlled, proof-of-concept trialThe Lancet · 2017
Remibrutinib versus teriflunomide in relapsing multiple sclerosis (REMODEL-1 and REMODEL-2): two randomised, phase 3 trialsThe Lancet · 2026
Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trialThe Lancet · 2026
Department of ErrorThe Lancet · 2026
Department of ErrorThe Lancet · 2026

More from The Lancet

More from McMaster University

More from University of Hong Kong

More from Instituut voor Tropische Geneeskunde

More from Suez Canal University

More from Western Cape Department of Health

More from Facultad Latinoamericana de Ciencias Argentina